{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-047567","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.232189+00:00","generated_at":"2026-06-03T09:38:34.330943+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M","bullets":["Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.","Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.","Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.","Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.","Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-047567","json":"https://secwatch.observer/filing/0000950170-24-047567.json","markdown":"https://secwatch.observer/filing/0000950170-24-047567.md","text":"https://secwatch.observer/filing/0000950170-24-047567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/vktx-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:38:34.330943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50a66246f8bee4dbead5f615d766d5ce294d4fe0","claim":"Viking Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}